瑞士，星期日, 2020年2月23日 7:30AM 欧洲中部时间
Demiurge致力于利用AI为2019新型冠状病毒（COVID-19）筛选新型候选治疗药物。基于Demiurge开发的精确广谱病毒学模型，我们对已发表的COVID-19研究和临床数据进行了深入的分析。
在之前所公布发现的基础上，我们今日公布瑞德西韦、磷酸氯喹、PI3K抑制剂做为针对2019新型冠状病毒（COVID-19）治疗方案的临床益处和临床风险的进一步发现：
- PI3K通路是细胞内病毒复制和细胞间病毒传播所必需的宿主细胞的微环境机制。
- 在目前已知的所有冠状病毒中，COVID-19对PI3K通路的依赖性最高，而且PI3K通路的代偿机制很少。
- 瑞德西韦作为目前在临床试验中的治疗药物，不会直接影响宿主细胞中的PI3K通路。瑞德西韦在用药过程中具有显著减少细胞内病毒复制的临床益处，但它也会诱导COVID-19潜伏于宿主细胞中。对于有中度至重度症状的COVID-19患者，瑞德西韦停药之后具有诱发细胞内病毒复制反弹的临床风险。
- 磷酸氯喹作为目前临床上使用的COVID-19治疗药物，同样不会直接影响宿主细胞中的PI3K通路。磷酸氯喹在用药过程中具有一定的减少细胞间病毒传播和减轻心脏并发症的临床益处，但也会一定程度上限制抗病毒免疫反应。对于轻度至中度症状并有基础疾病的COVID-19患者， 磷酸氯喹在用药过程中具有不可耐受毒副作用的临床风险。
- PI3K抑制剂做为目前尚未在临床试验中或临床上使用的COVID-19治疗药物，直接抑制异常启动的PI3K通路并使宿主细胞微环境正常化。PI3K抑制剂在用药过程中具有强效抑制细胞内病毒复制和细胞间病毒扩散的临床益处，而不会诱发病毒潜伏于宿主细胞中，也不会限制抗病毒免疫反应。对于无症状并有基础疾病的COVID-19患者, 某些PI3K抑制剂在用药过程中具有一定毒副作用的临床风险。
在慢性病领域，药物专利的排他性和药物销售的独家性有效激励医药企业完成漫长而昂贵的新药开发，最终普惠大众。但是在流行病领域，时间是最为稀缺的要素。公众对治疗药物需求的紧迫性和药企对治疗药物供给的独家性通常在时间上是难以兼顾的。然而我们相信，在对抗流行病对生命的威胁时，深耕于医药事业的企业和个人都会将公众福祉放在首位。争分夺秒，阻击病毒。
因此，面对COVID-19, Demiurge决定第一时间向公众公布我们上述的进一步发现，放弃平常时期申请专利保护、独家权益合作等环节。以期能尽吾之所长，协同业界上下游，尽快开展PI3K抑制剂的三期临床试验。
关于Demiurge Technologies AG
AI已成为一种新型强大的技术方法，它可以帮助人类更深入地了解疾病和更快地发现药物。但AI必须经过严格的测试，在公众的监督下证明其价值。Demiurge已经完成了90多个三期临床试验结果的预测，实现了大于80%的准确率。同时，我们在推特（Twitter）上邀请公众参与见证我们对正在进行中的全球新药三期临床试验结果的预测（@DemiurgeTech）。
因此，我们在这里基于AI提出了瑞德西韦、磷酸氯喹、PI3K抑制剂做为针对2019新型冠状病毒（COVID-19）治疗方案的临床益处和临床风险的科学假设，并公开邀请世界各地通过随机对照临床试验的方式，验证基于PI3K抑制剂的COVID-19治疗方案是否比瑞德西韦或磷酸氯喹更加安全有效。Demiurge敦促大众在任何相关临床试验结果公布之前，不应将任何PI3K抑制剂等同于COVID-19的治疗药物擅自使用。
Disclaimers
This material is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. These statements are not guarantees of future performance, condition or results. Figures and graphs in this presentation are for illustration only and are may not match the actual scale. This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’,‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees. Demiurge Technologies AG (“Demiurge”) undertakes no duty or obligation to publicly update or revise the forward-looking statements or other information contained in this presentation. You should not view information related to the past performance of Demiurge and its affiliates or information about the market, as indicative of future results, the achievement of which cannot be assured. While some information used in this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Amounts and percentages may reflect rounding adjustments and consequently totals may not appear to sum. None of the information in this presentation does, by itself, constitute an offering or an offering circular according to Article 652a of the Swiss Code of Obligations and is subject to change without notice. Any offer or solicitation with respect to any securities that may be issued by Demiurge will be made only by means of definitive offering memoranda or prospectus, which will be provided to prospective investors and will contain material information that is not set forth herein, including risk factors relating to any such investment. Before making an investment, you must obtain and carefully read all information needed to evaluate the investment, including, but not limited to the documents providing important disclosures regarding risks, fees and expenses. An investment in Demiurge may be volatile and can suffer from adverse or unexpected market moves or other adverse events. Investors may suffer the loss of their entire investment. An investment in Demiurge will be discrete from an investment in any funds or other investment programs managed by Demiurge and the results or performance of such other investment programs is not indicative of the results or performance that will be achieved by Demiurge or such investment programs.
* 中英文通告的最终解释以英文为准
